Pds biotech announces expanded interim data in pds0101 triple combination phase 2 trial targeting advanced hpv-positive cancers

66% of hpv 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 months 66% of hpv 16-positive checkpoint inhibitor refractory patients are alive at median follow up of 16 months

PDSB Ratings Summary

PDSB Quant Ranking